Weight Loss with Liraglutide 3.0 mg is Associated with Improved Health-related Quality of Life (HRQoL) and Treatment Satisfaction in Adults with Overweight/Obesity and Type 2 Diabetes (T2D): The SCALE Diabetes Randomized, Double-Blind, Placebo-Controlled 56-Week Trial

Andrew Lewin, M J Davies,Bruce W Bode,Sean Wharton,Ralph A Defronzo,Maureen Noctor,Damir Boras,Robert F Kushner

Canadian Journal of Diabetes（2015）

引用 0|浏览11

暂无评分

摘要

This study examined the impact of weight loss with liraglutide 3.0 mg, as an adjunct to diet and exercise (D&E), compared with placebo and liraglutide 1.8 mg on health-related quality of life (HRQoL) in overweight/obese adults with type 2 diabetes.

查看译文

关键词

weight loss,liraglutide,overweight/obesity,scale diabetes,health-related,double-blind,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要